What's Happening?
The seven-member Expedition 73 crew aboard the International Space Station has commenced a new biotechnology investigation involving liver tissue research. Following the docking of SpaceX's Dragon spacecraft, NASA Flight Engineer Mike Fincke, along with colleagues Jonny Kim and Zena Cardman, and JAXA's Kimiya Yui, began unpacking and preserving time-sensitive research samples. The investigation, known as MVP Cell-07, aims to study the behavior of bioprinted liver tissues in microgravity, potentially benefiting astronaut health and patient care on Earth. Additionally, preparations are underway for Dragon's reboost of the station's orbit scheduled for September.
AD
Why It's Important?
This research is significant as it explores the maturation of vascularized liver tissue in zero gravity, which could lead to advancements in biotechnology and healthcare. The findings may improve long-term astronaut health and enhance medical treatments on Earth. The Dragon spacecraft's reboost capability is crucial for maintaining the station's orbit, ensuring continued scientific research and international collaboration in space exploration.
What's Next?
The crew will continue to unpack and analyze the research samples delivered by Dragon. The upcoming reboost in September will demonstrate Dragon's ability to maintain the station's altitude, a critical function for ongoing operations. The results of the liver tissue research will be closely monitored for potential applications in space and terrestrial medicine.
